Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.48 |
| ▸ | PPARG | P37231 | 10/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | DBH | P09172 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11949592 | 0.85 | SLC2A1 (0.47) | KCNH2SLC2A1PLAUPLGERBB2 | |
| SCHEMBL15627017 | 0.85 | APP (0.50) | KCNH2EPHX2PLAUPLGERBB2 | |
| SCHEMBL11949599 | 0.82 | DPP4 (0.53) | EPHX2PPARGMAOBSLC2A1EGFR | |
| SCHEMBL20172385 | 0.81 | EPHX2 (0.53) | EPHX2PPARGMAOBSLC2A1EGFR | |
| SCHEMBL3507375 | 0.80 | EGFR (0.62) | EPHX2PPARGMAOBSLC2A1EGFR | |
| SCHEMBL6085951 | 0.80 | EGFR (0.51) | EPHX2PPARGMAOBSLC2A1EGFR | |
| SCHEMBL1104768 | 0.79 | HTR6 (0.55) | EPHX2PPARGMAOBSLC2A1EGFR | |
| SCHEMBL31258087 | 0.79 | HTR6 (0.55) | EPHX2PPARGMAOBSLC2A1EGFR | |
| SCHEMBL14093199 | 0.78 | GABRA1 (0.52) | KCNH2MAOBEGFR | |
| SCHEMBL11949596 | 0.77 | EGFR (0.50) | EPHX2PPARGEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524956-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210047303-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | KANION USA INC. | 2021-02-18 | — | — | US | disclosed |
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2016-02-04 | — | — | US | disclosed |
| US-9187459-B2 | Quinazoline-7-ether compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187459-B2 | Quinazoline-7-ether compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9090588-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090588-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | KCNH2 3268/4885EPHX2 2602/4885PPARG 1788/4885 |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | KCNH2 3268/4885EPHX2 2602/4885PPARG 1788/4885 |
| US-20140221406-A1 | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | ABL1, ERBB4, ERBB2 | KCNH2 4630/4885EPHX2 2114/4885PPARG 1622/4885 |
| US-11524956-B2 | Alkyne substituted quinazoline compound and methods of use | ERBB2, ERBB4, ERBB3 | KCNH2 3268/4885EPHX2 2602/4885PPARG 1788/4885 |
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | KCNH2 3268/4885EPHX2 2602/4885PPARG 1788/4885 |
| US-20210047303-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | KCNH2 3268/4885EPHX2 2602/4885PPARG 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.